Evidence map›Paper›PMID 30051164›Full record

Observational studyJournal of thrombosis and thrombolysis2018

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Larry R Jackson, Sunghee Kim, Peter Shrader, Rosalia Blanco, Laine Thomas, Michael D Ezekowitz, Jack Ansell, Gregg C Fonarow, Bernard J Gersh, Alan S Go and 5 more

Abstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of thrombosis and thrombolysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Larry R JacksonDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. larry.jackson@dm.duke.edu.ORCID http://orcid.org/0000-0002-0195-1081
Sunghee KimDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Peter ShraderDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Rosalia BlancoDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Laine ThomasDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Michael D EzekowitzLankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, PA, USA.
Jack AnsellHofstra North Shore/LIJ School of Medicine, Hempstead, New York, USA.
Gregg C FonarowUCLA Division of Cardiology, Los Angeles, CA, USA.
Bernard J GershMayo Clinic College of Medicine, Rochester, MN, USA.
Alan S GoKaiser Permanente, Oakland, CA, USA.
Peter R KoweyLankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, PA, USA.
Kenneth W MahaffeyDivision of Cardiovascular Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA.
Elaine M HylekBoston University School of Medicine, Boston, MA, USA.
Eric D PetersonDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Jonathan P PicciniDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anticoagulation is highly effective for the prevention of stroke in patients with atrial fibrillation (AF) but it is dependent on patients continuing therapy. While studies have demonstrated suboptimal therapeutic persistence on warfarin, few have studied persistence rates with non vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran. We examined rates of continued use of dabigatran versus warfarin over 1 year among AF patients in the ORBIT-AF registry between June 29, 2010 and August 09, 2011. Multivariable logistic regression analysis was used to identify characteristics associated with 1-year persistent use of dabigatran therapy or warfarin. At baseline, 6.4 and 93.6% of 7150 AF patients were on dabigatran and warfarin, respectively. At 12 months, dabigatran-treated patients were less likely to have continued their therapy than warfarin-treated patients [Adjusted persistence rates: 66% (95% CI 60-72) vs. 82% (95% CI 80-84), p < .0001]. Predictors of dabigatran persistence included: CHA

Indexed as

AgedAnticoagulantsAtrial FibrillationDabigatranGastrointestinal DiseasesHemorrhageHumansPatient ComplianceRegistriesStrokeWarfarinAnticoagulantsDabigatranWarfarinAtrial fibrillationDabigatranOral anticoagulationWarfarin

Identifiers

PMID30051164
PMCPMC6182370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.